Issued on behalf of Avant Technologies Inc.
Equity Insider News Commentary -The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that target genetic diseases at their source[1]. The FDA approved three transformative cell therapies this December alone, marking an inflection point where living medicine moves from experimental concept to commercial reality[2]. This revolution in restorative biology defines the pipelines of Avant Technologies, Inc. (OTCQB: AVAI), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), CRISPR Therapeutics (NASDAQ: CRSP), Prime Medicine, Inc. (NASDAQ: PRME), and Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
| 
1.24% $5.82
2.59%
